Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stake Lessened by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 118,238 shares of the biopharmaceutical company's stock after selling 45,000 shares during the quarter. Ultragenyx Pharmaceutical accounts for about 1.2% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 20th largest holding. Blue Owl Capital Holdings LP owned approximately 0.13% of Ultragenyx Pharmaceutical worth $4,974,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Syon Capital LLC acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at $310,000. Dark Forest Capital Management LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $459,000. Silverarc Capital Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $5,233,000. Hsbc Holdings PLC lifted its position in Ultragenyx Pharmaceutical by 195.1% during the 4th quarter. Hsbc Holdings PLC now owns 47,516 shares of the biopharmaceutical company's stock worth $1,975,000 after acquiring an additional 31,416 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in Ultragenyx Pharmaceutical by 13.5% in the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after acquiring an additional 2,835 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RARE shares. Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Wedbush restated a "neutral" rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $92.79.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 25,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now directly owns 2,158,985 shares of the company's stock, valued at $91,713,682.80. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares in the company, valued at $2,116,156.50. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 in the last ninety days. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded up $0.45 during mid-day trading on Friday, hitting $38.09. The company had a trading volume of 575,372 shares, compared to its average volume of 818,321. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The stock has a market cap of $3.58 billion, a price-to-earnings ratio of -6.01 and a beta of 0.61. The firm's 50 day simple moving average is $37.79 and its two-hundred day simple moving average is $43.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.